$LVT Partners With Canntab To Combat Canadian Opioid Crisis Levitee Labs $LVT/$LVT.C has partnered with medicinal cannabis company Canntab Therapeutics to continue the companies efforts of combating the opioid crisis in Canada.
As per the agreement, $LVT will offer Canntab’s lineup of therapeutics throughout all of its pharmacies and clinics in Western Canada. The partnership is anticipated to enhance patient care and drive additional revenue.
$LVT executive director Noha ElSayed had the following to say about the announcement of the agreement: “We share a vision with Canntab to play a meaningful role in flattening the curve of the opioid crisis in Canada by tapering use of addictive painkillers through the substitution of viable alternatives, which can include cannabinoids like CBD and THC and combination thereof.”
Shares of $LVT are currently up 8% following the announcement, and I’m watching for signs that shares will trend into a reversal from current all-time lows.
$LVT is currently trading at a price of $.270 and the company is valued at an MCAP of $21.63 million.
https://ceo.ca/@nasdaq/levitee-labspartners-withcanntab-therapeutics-to